Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Viking Therapeutics, Inc.VKTX · Entity 4067 | Chief Financial Officer | July 28, 2026 | July 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Viking Therapeutics, Inc.
Report date July 28, 2026 · Filed July 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 233,421 |
Reported balance
After 2026-07-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-28 · Grant · Acquired 31,667 · Balance 233,421 F1: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal. F2: Includes 11,055 shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan and 808 shares acquired on May 20, 2026 pursuant to the Issuer's 2024 Employee Stock Purchase Plan |
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 212,204 |
Reported balance
After 2026-07-29 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-07-29 · Sale · Disposed 21,217 · Balance 212,204 F3: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.30 to $33.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal.
F2: Includes 11,055 shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan and 808 shares acquired on May 20, 2026 pursuant to the Issuer's 2024 Employee Stock Purchase Plan
F3: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.30 to $33.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2026 Filed Jul 29, 2026 20:06 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 21,217 | $33.47 | $710,141.48 |
DisclosureSEC source: 0001193125-26-324447 · ownership.xml · nonDerivative · entry 2 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,204 F3 · shares: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.30 to $33.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote. Read SEC document |
| July 28, 2026 Filed Jul 29, 2026 20:06 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 31,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-324447 · ownership.xml · nonDerivative · entry 1 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 233,421 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal. F2 · balance_after: Includes 11,055 shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan and 808 shares acquired on May 20, 2026 pursuant to the Issuer's 2024 Employee Stock Purchase Plan Read SEC document |
| January 05, 2026 Filed Jan 5, 2026 20:31 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 1,500 | $32.09 | $48,133.05 |
DisclosureSEC source: 0001193125-26-003116 · ownership.xml · nonDerivative · entry 6 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,891 F4 · shares: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3. F8 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.88 to $35.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 05, 2026 Filed Jan 5, 2026 20:31 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 10,300 | $34.24 | $352,634.92 |
DisclosureSEC source: 0001193125-26-003116 · ownership.xml · nonDerivative · entry 5 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,371 F4 · shares: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3. F7 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.88 to $34.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 05, 2026 Filed Jan 5, 2026 20:31 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 13,900 | $33.38 | $464,020.92 |
DisclosureSEC source: 0001193125-26-003116 · ownership.xml · nonDerivative · entry 4 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,671 F4 · shares: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.88 to $33.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 05, 2026 Filed Jan 5, 2026 20:31 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 31,961 | $32.30 | $1,032,180.50 |
DisclosureSEC source: 0001193125-26-003116 · ownership.xml · nonDerivative · entry 3 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,571 F4 · shares: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.88 to $32.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 20:31 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 91,000 | $0.00 Strike: $35.42 | $0.00 |
DisclosureSEC source: 0001193125-26-003116 · ownership.xml · derivative · entry 7 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,000 Underlying: Common Stock · 91,000 shares Expires 2036-01-02 F9 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 20:31 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 32,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-003116 · ownership.xml · nonDerivative · entry 2 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,532 F3 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on January 2, 2026, upon the achievement of a non-financial performance goal and a second performance restricted stock unit award that was granted on January 3, 2025, 1.665% of which vested on January 2, 2026, upon the partial achievement of a non-financial performance goal. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 20:31 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 41,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-003116 · ownership.xml · nonDerivative · entry 1 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,483 F1 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. F2 · balance_after: Includes 104 shares acquired on May 20, 2025 and 787 shares acquired on November 20, 2025 pursuant to the Issuer's 2024 Employee Stock Purchase Plan. Read SEC document |
| October 28, 2025 Filed Oct 28, 2025 19:47 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 6,185 | $35.00 | $216,480.57 |
DisclosureSEC source: 0001193125-25-254298 · ownership.xml · nonDerivative · entry 2 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,592 F2 · shares: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.6525 to $35.3939, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 19:47 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 11,117 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-254298 · ownership.xml · nonDerivative · entry 1 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,777 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2025, 33.33% of which vested on October 27, 2025 upon the achievement of a non-financial performance goal and 15% of which vested also on October 27, 2025 upon the partial achievement of a non-financial performance goal. Read SEC document |
| July 03, 2025 Filed Jul 3, 2025 15:31 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 4,266 | $27.76 | $118,428.43 |
DisclosureSEC source: 0000950170-25-093792 · ownership.xml · nonDerivative · entry 2 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,660 F2 · shares: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.72 to $27.785, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote. Read SEC document |
| July 02, 2025 Filed Jul 3, 2025 15:31 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 7,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-093792 · ownership.xml · nonDerivative · entry 1 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,926 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2025, 33.33% of which vested on July 2, 2025 upon the achievement of a non-financial performance goal. Read SEC document |
| January 06, 2025 Filed Jan 6, 2025 20:14 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 4,700 | $43.32 | $203,601.18 |
DisclosureSEC source: 0000950170-25-002485 · ownership.xml · nonDerivative · entry 4 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,259 F4 · shares: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards and certain performance restricted stock unit awards. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.20 to $43.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 06, 2025 Filed Jan 6, 2025 20:14 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 45,609 | $42.69 | $1,946,993.48 |
DisclosureSEC source: 0000950170-25-002485 · ownership.xml · nonDerivative · entry 3 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,959 F4 · shares: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards and certain performance restricted stock unit awards. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.19 to $43.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 03, 2025 Filed Jan 6, 2025 20:14 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 37,200 | $0.00 Strike: $42.89 | $0.00 |
DisclosureSEC source: 0000950170-25-002485 · ownership.xml · derivative · entry 5 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,200 Underlying: Common Stock · 37,200 shares Expires 2035-01-03 F7 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 03, 2025 Filed Jan 6, 2025 20:14 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 21,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002485 · ownership.xml · nonDerivative · entry 2 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,568 F3 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2024, 33.33% of which vested on January 3, 2025 upon the achievement of a non-financial performance goal. Read SEC document |
| January 03, 2025 Filed Jan 6, 2025 20:14 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 44,533 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002485 · ownership.xml · nonDerivative · entry 1 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,901 F1 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. F2 · balance_after: Includes 2 shares acquired on November 20, 2024 pursuant to the Issuer's 2024 Employee Stock Purchase Plan. Read SEC document |
| October 28, 2024 Filed Oct 28, 2024 21:48 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 51,000 | $0.00 Strike: $8.52 | $0.00 |
DisclosureSEC source: 0000950170-24-117885 · ownership.xml · derivative · entry 16 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,000 Underlying: Common Stock · 51,000 shares Expires 2033-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person. F12 · derivative.exercise_date: 25% of the shares subject to the option vested or will vest on each anniversary of the grant date. Read SEC document |
| October 28, 2024 Filed Oct 28, 2024 21:48 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $5.80 | $0.00 |
DisclosureSEC source: 0000950170-24-117885 · ownership.xml · derivative · entry 15 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,000 shares Expires 2031-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person. F11 · derivative.exercise_date: One-third of the shares subject to the option vested on each anniversary of the grant date. Read SEC document |
| October 28, 2024 Filed Oct 28, 2024 21:48 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,251 | $0.00 Strike: $4.68 | $0.00 |
DisclosureSEC source: 0000950170-24-117885 · ownership.xml · derivative · entry 14 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,251 shares Expires 2030-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person. F10 · derivative.exercise_date: 25% of the shares subject to the option vested on each anniversary of the grant date. Read SEC document |
| October 28, 2024 Filed Oct 28, 2024 21:48 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,750 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0000950170-24-117885 · ownership.xml · derivative · entry 13 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,750 shares Expires 2030-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person. F10 · derivative.exercise_date: 25% of the shares subject to the option vested on each anniversary of the grant date. Read SEC document |
| October 28, 2024 Filed Oct 28, 2024 21:48 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 1,206 | $81.44 | $98,222.31 |
DisclosureSEC source: 0000950170-24-117885 · ownership.xml · nonDerivative · entry 12 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,366 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.35 to $81.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 28, 2024 Filed Oct 28, 2024 21:48 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 7,967 | $80.65 | $642,544.92 |
DisclosureSEC source: 0000950170-24-117885 · ownership.xml · nonDerivative · entry 11 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,572 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.30 to $81.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 28, 2024 Filed Oct 28, 2024 21:48 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 6,050 | $79.78 | $482,664.77 |
DisclosureSEC source: 0000950170-24-117885 · ownership.xml · nonDerivative · entry 10 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,539 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.29 to $80.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 28, 2024 Filed Oct 28, 2024 21:48 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 15,825 | $78.69 | $1,245,280.33 |
DisclosureSEC source: 0000950170-24-117885 · ownership.xml · nonDerivative · entry 9 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,589 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.27 to $79.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 28, 2024 Filed Oct 28, 2024 21:48 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 23,082 | $77.68 | $1,793,018.99 |
DisclosureSEC source: 0000950170-24-117885 · ownership.xml · nonDerivative · entry 8 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 180,414 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.27 to $78.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 28, 2024 Filed Oct 28, 2024 21:48 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 9,265 | $76.94 | $712,802.78 |
DisclosureSEC source: 0000950170-24-117885 · ownership.xml · nonDerivative · entry 7 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 203,496 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.27 to $77.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 28, 2024 Filed Oct 28, 2024 21:48 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 18,620 | $75.79 | $1,411,135.32 |
DisclosureSEC source: 0000950170-24-117885 · ownership.xml · nonDerivative · entry 6 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 212,761 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.24 to $76.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 28, 2024 Filed Oct 28, 2024 21:48 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 49,672 | $74.56 | $3,703,494.65 |
DisclosureSEC source: 0000950170-24-117885 · ownership.xml · nonDerivative · entry 5 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 231,381 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.24 to $75.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 28, 2024 Filed Oct 28, 2024 21:48 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 51,000 | $8.52 | $434,520.00 |
DisclosureSEC source: 0000950170-24-117885 · ownership.xml · nonDerivative · entry 4 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 281,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person. Read SEC document |
| October 28, 2024 Filed Oct 28, 2024 21:48 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 26,000 | $5.80 | $150,800.00 |
DisclosureSEC source: 0000950170-24-117885 · ownership.xml · nonDerivative · entry 3 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 230,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person. Read SEC document |
| October 28, 2024 Filed Oct 28, 2024 21:48 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 4,251 | $4.68 | $19,894.68 |
DisclosureSEC source: 0000950170-24-117885 · ownership.xml · nonDerivative · entry 2 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 204,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person. Read SEC document |
| October 28, 2024 Filed Oct 28, 2024 21:48 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 12,750 | $7.77 | $99,067.50 |
DisclosureSEC source: 0000950170-24-117885 · ownership.xml · nonDerivative · entry 1 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 199,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person. Read SEC document |
| July 30, 2024 Filed Jul 31, 2024 16:05 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 500 | $58.71 | $29,355.00 |
DisclosureSEC source: 0000950170-24-088538 · ownership.xml · nonDerivative · entry 5 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,052 F3 · shares: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock unit awards. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.54 to $58.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 30, 2024 Filed Jul 31, 2024 16:05 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 2,974 | $57.71 | $171,629.54 |
DisclosureSEC source: 0000950170-24-088538 · ownership.xml · nonDerivative · entry 4 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,552 F3 · shares: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock unit awards. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.46 to $58.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 30, 2024 Filed Jul 31, 2024 16:05 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 12,662 | $56.96 | $721,227.52 |
DisclosureSEC source: 0000950170-24-088538 · ownership.xml · nonDerivative · entry 3 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,526 F3 · shares: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock unit awards. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.46 to $57.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 16:05 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 21,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-088538 · ownership.xml · nonDerivative · entry 2 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,188 F2 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2024, 33.33% of which vested on July 29, 2024 upon the achievement of a non-financial performance goal. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 16:05 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-088538 · ownership.xml · nonDerivative · entry 1 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,521 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 4, 2021, 33.33% of which vested on July 29, 2024 upon the achievement of a non-financial performance goal. Read SEC document |
| May 03, 2024 Filed May 3, 2024 20:51 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001209191-24-005522 · doc4.xml · derivative · entry 8 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 30,000 shares Expires 2032-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2024. F6 · derivative.exercise_date: 25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date. Read SEC document |
| May 03, 2024 Filed May 3, 2024 20:51 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,249 | $0.00 Strike: $4.68 | $0.00 |
DisclosureSEC source: 0001209191-24-005522 · doc4.xml · derivative · entry 7 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,251 Underlying: Common Stock · 4,249 shares Expires 2030-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2024. F6 · derivative.exercise_date: 25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date. Read SEC document |
| May 03, 2024 Filed May 3, 2024 20:51 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 847 | $76.07 | $64,434.93 |
DisclosureSEC source: 0001209191-24-005522 · doc4.xml · nonDerivative · entry 6 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 174,854 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.995 to $76.135, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 03, 2024 Filed May 3, 2024 20:51 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 17,238 | $75.49 | $1,301,241.46 |
DisclosureSEC source: 0001209191-24-005522 · doc4.xml · nonDerivative · entry 5 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,701 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.985 to $75.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 03, 2024 Filed May 3, 2024 20:51 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 45,570 | $74.44 | $3,392,444.98 |
DisclosureSEC source: 0001209191-24-005522 · doc4.xml · nonDerivative · entry 4 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,939 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.98 to $74.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 03, 2024 Filed May 3, 2024 20:51 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 3,101 | $73.49 | $227,886.60 |
DisclosureSEC source: 0001209191-24-005522 · doc4.xml · nonDerivative · entry 3 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 238,509 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.97 to $73.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 03, 2024 Filed May 3, 2024 20:51 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 30,000 | $4.88 | $146,400.00 |
DisclosureSEC source: 0001209191-24-005522 · doc4.xml · nonDerivative · entry 2 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 241,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2024. Read SEC document |
| May 03, 2024 Filed May 3, 2024 20:51 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 4,249 | $4.68 | $19,885.32 |
DisclosureSEC source: 0001209191-24-005522 · doc4.xml · nonDerivative · entry 1 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2024. Read SEC document |
| March 27, 2024 Filed Mar 27, 2024 20:50 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 16,610 | $83.34 | $1,384,277.40 |
DisclosureSEC source: 0001209191-24-005116 · doc4.xml · nonDerivative · entry 2 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,361 F2 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units. Read SEC document |
| March 27, 2024 Filed Mar 27, 2024 20:50 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 31,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-005116 · doc4.xml · nonDerivative · entry 1 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,971 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on March 27, 2024 upon the achievement of a non-financial performance goal. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 19:50 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 20,093 | $85.22 | $1,712,325.46 |
DisclosureSEC source: 0001209191-24-004231 · doc4.xml · nonDerivative · entry 2 ZANTE GREG · CIK 0001264949 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,304 F2 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.